Para ello aventuro tres posturas analticas posibles, que espero despierten el nimo de otros investigadores. ❋ Admin (2009)
However, a short waterside path runs into the village of Cabanas where the boardwalk is lined with restaurants like Pedro's and No é lia e Jer ó nimo which use locally caught seafood to serve up traditional meals like octopus fritters with cilantro rice, or white beans and whelks. ❋ Unknown (2010)
Si Tatay Tonyo nimo nagkatusok-tusok sa alpiler sa imong lampin. ❋ Merlie Alunan (2006)
Inigmata nimo unya, panahon nga mangitngit na, basin manungha ra na sila, tagak nga mga bituon, makab-ot ra sa imong kamot ug mga mata. ❋ Merlie Alunan (2006)
However, Geronimo was hyphenated at a line break, so Gero appeared on one line and nimo on the next, and unfortunately, Mr. Fairbain read it as Jair-oh-NEEM-oh. ❋ E. L. Konigsburg (1996)
In August 2008, YMI announced preliminary results from a Phase 2 study of nimo in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). ❋ Unknown (2009)
Unsa imong plano buhaton pagka human nimo mag Internet? ❋ Unknown (2009)
As of late 2007, a consortium of licensees was also formed to share late-stage clinical trials in order to rapidly recruit patients in numerous countries and familiarize oncologists with the drug as part of the clinical development process for nimo in developed markets. ❋ Unknown (2009)
Nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting monoclonal antibody or MAb) is currently being evaluated in 11 ❋ Unknown (2009)
In April 2009, YMI presented data at AACR that demonstrated bivalent binding by nimo results in differential recognition of EGFR over-expressing cancer cells and normal cells, which is in contrast to observations with Erbitux, whose high affinity monovalent interaction prevents it from discriminating between the cells. ❋ Unknown (2009)
Despite the disappointing Phase 2 mCRC results last year, nimo continues to demonstrate a best-in-class safety profile among EGFR antibodies with a differentiated affinity for EGFR that is targeted toward tumor cells rather than healthy cells such as the skin with lower EGFR expression. ❋ Unknown (2009)
Shares of YMI declined by about 20% on heavy volume on the Phase 2 mCRC trial news last year, as many traders and investors were hoping for blockbuster survival results in the study were disappointed with a median PFS of 12 months for nimo versus 18 months for Erbitux in the BOND I trial. ❋ Unknown (2009)
The major safety advantage and discriminate EGFR binding of nimo with best-in-class potential. the global consortium behind nimo clinical development, which includes 11 Phase 2 or 3 trials being conducted by YMI (3) or its licensees (8), including Daichii-Sankyo [TYO: 4568] ❋ Unknown (2009)
Marketing approval of nimo in 18 countries with a goal of approval in major market by ❋ Unknown (2009)
At current valuations, the market currently places no value on nimo or AeroLEF with YMI trading a discount to its cash since reporting the Phase 2 mCRC results last year. ❋ Unknown (2009)
Pending clinical data for nimo, including the milestones outlined above included nine studies through 2010. ❋ Unknown (2009)
However, the following factors in favor of YMI support the current share price and provide for a multitude of potentially positive clinical development catalysts over the next year or so as t he company works toward its goal of nimo approval in a major market by 2010-2011. ❋ Unknown (2009)
